Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer’s Disease

Economic Evaluation of the Impact of Memantine on Time to Nursing Home Admission in the Treatment of Alzheimer Disease

(2017) Jean Lachaine et al.   CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE

Cost-Effectiveness of Donepezil in the Treatment of Mild or Moderate Alzheimer's Disease

(2017) Julio López-Bastida et al.   JOURNAL OF ALZHEIMERS DISEASE

Early cost-utility analysis of general and cerebrospinal fluid-specific Alzheimer's disease biomarkers for hypothetical disease-modifying treatment decision in mild cognitive impairment

(2015) Ron L.H. Handels et al.   Alzheimers & Dementia

A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence

(2015) Jacob S. Buckley et al.   DRUGS & AGING

Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia

(2015) Willemijn J. Jansen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of Technology Appraisal No. 111): a systematic review and economic model.

(2014) M Bond et al.   HEALTH TECHNOLOGY ASSESSMENT

Harmonized diagnostic criteria for Alzheimer's disease: recommendations

(2014) J. C. Morris et al.   JOURNAL OF INTERNAL MEDICINE

Evaluating Disease-Modifying Agents: A Simulation Framework for Alzheimer’s Disease

(2014) Shien Guo et al.   PHARMACOECONOMICS

Decision-Analytic Models: Current Methodological Challenges

(2014) J. Jaime Caro et al.   PHARMACOECONOMICS

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures

(2014) Jeffrey L Cummings et al.   Alzheimers Research & Therapy

Preclinical Biomarkers in Alzheimer Disease

(2014) Susan M. Resnick   JAMA Neurology

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

(2013) Clifford R Jack et al.   LANCET NEUROLOGY

Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement

(2013) Don Husereau et al.   PHARMACOECONOMICS

Revised Criteria for Mild Cognitive Impairment May Compromise the Diagnosis of Alzheimer Disease Dementia

(2012) John C. Morris   ARCHIVES OF NEUROLOGY

Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation

(2012) Susanne Hartz et al.   BMC Neurology

Economic Evaluation of Treatment Options in Patients with Alzheimerʼs Disease

(2012) Laura Pouryamout et al.   DRUGS

Genetic Testing in Combination with Preventive Donepezil Treatment for Patients with Amnestic Mild Cognitive Impairment

(2012) Sandjar Djalalov et al.   Molecular Diagnosis & Therapy

Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease

(2012) Randall J. Bateman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6

(2012) Andrew H. Briggs et al.   VALUE IN HEALTH

Conceptualizing a Model: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2

(2012) Mark Roberts et al.   VALUE IN HEALTH

Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7

(2012) David M. Eddy et al.   VALUE IN HEALTH

Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time

(2012) Suzanne B Hendrix   Alzheimers Research & Therapy

Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway

(2011) B. Rive et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Model-Based Economic Evaluation in Alzheimer's Disease: A Review of the Methods Available to Model Alzheimer's Disease Progression

(2011) Colin Green et al.   VALUE IN HEALTH

Cost Effectiveness of Donepezil in the Treatment of Mild to Moderate Alzheimerʼs Disease

(2010) Denis Getsios et al.   PHARMACOECONOMICS

Cost effectiveness of memantine in Alzheimer's disease in the UK

(2010) B. Rive et al.   JOURNAL OF MEDICAL ECONOMICS

Modelling the clinical and economic implications of galantamine in the treatment of mild-to-moderate Alzheimer's disease in Germany

(2010) Shien Guo et al.   JOURNAL OF MEDICAL ECONOMICS

Health economic effect of donepezil treatment for CDR 0.5 converters to Alzheimer's disease as shown by the Markov model

(2009) Masashi Kasuya et al.   ARCHIVES OF GERONTOLOGY AND GERIATRICS

Biracial Population Study of Mortality in Mild Cognitive Impairment and Alzheimer Disease

(2009) Robert S. Wilson et al.   ARCHIVES OF NEUROLOGY

Modeling the Cost-Effectiveness of Galantamine for Mild to Moderately Severe Alzheimer's Disease in Korea

(2009) Guk-Hee Suh   VALUE IN HEALTH

Decision analytic models for Alzheimer's disease: State of the art and future directions

(2008) Joshua T. Cohen et al.   Alzheimers & Dementia

Systematic review of economic evaluations of Alzheimer’s disease medications

(2008) Mark Oremus   Expert Review of Pharmacoeconomics & Outcomes Research